A Phase II Study of Cetuximab (Erbitux®) plus FOLFIRI for Irinotecan and Oxaliplatin-refractory Metastatic Colorectal Cancer

We have evaluated the efficacy and safety of cetuximab plus FOLFIRI for irinotecan and oxaliplatin-refractory colorectal cancers. From September 2004 to February 2006, 31 patients with metastatic colorectal cancer were treated with cetuximab (400 mg/m(2) intravenously [IV] over 2 hr on day 1 followe...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Koo, Dong Hoe, Lee, Jae-Lyun, Kim, Tae Won, Chang, Heung Moon, Ryu, Min-Hee, Lee, Sung Sook, Kim, Min Kyoung, Sym, Sun Jin, Lee, Jung Shin, Kang, Yoon-Koo
Natura: Artigo
Lingua:Inglês
Pubblicazione: The Korean Academy of Medical Sciences 2007
Soggetti:
Original Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2694394/
https://ncbi.nlm.nih.gov/pubmed/17923763
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3346/jkms.2007.22.S.S98
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi